Cell Therapeutics IncCTIC:NAQ

3.18
0.15 / 4.50%
2.93m
194.44%
2.12
Close in USDToday's changeShares traded1 year changeBeta
As of Apr 23 2014 21:00 BST.Data delayed by at least 15 minutes.

Consensus recommendation

As of Apr 18, 2014, the consensus forecast amongst 3 polled investment analysts covering Cell Therapeutics Inc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 04, 2013. The previous consensus forecast advised investors to purchase equity in Cell Therapeutics Inc.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy1
Outperform1
Hold1
Underperform0
Sell0
No opinion0

Research Reports

S&P Capital IQ Quantitative Report
Ford Investor Services, Inc.

Share price forecast

The 3 analysts offering 12 month price targets for Cell Therapeutics Inc have a median target of 4.50, with a high estimate of 6.00 and a low estimate of 4.00. The median estimate represents a 41.51% increase from the last price of 3.18. View Full Financials

High+88.7 %6.00
Med+41.5 %4.50
Low+25.8 %4.00

Dividends

Dividend information is not available for Cell Therapeutics Inc. View Full Financials

Earnings history & estimates

On Mar 04, 2014, Cell Therapeutics Inc reported 4th quarter 2013 earnings of 0.08 per share. This result exceeded the -0.16 consensus loss of the 3 analysts covering the company and outperformed last year's 4th quarter results by 0.27.
The next earnings announcement is expected on Apr 29, 2014. View Full Interim Financials

Average growth rate-2.28%

Cell Therapeutics Inc reported annual 2013 losses of -0.43 per share on Mar 04, 2014. View Full Annual Financials

Average growth rate+45.22%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

Cell Therapeutics, Inc. had 4th quarter 2013 revenues of 520.00k. This missed the 1.26m consensus estimate of the 3 analysts following the company. This was 43.65% above the prior year's 4th quarter results. View Full Interim Financials

Average growth rate-3.63%

Cell Therapeutics, Inc. had revenues for the full year 2013 of 2.31m. View Full Annual Financials

Average growth rate+66.25%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.